From the Guidelines
Mydayis is a prescription medication used to treat attention-deficit/hyperactivity disorder (ADHD) in patients 13 years and older, containing a mixture of amphetamine salts in a triple-bead extended-release formulation.
Key Characteristics of Mydayis
- It is designed to provide symptom control for up to 16 hours, taken once daily in the morning.
- Starting doses are usually at 12.5 mg for adolescents and 12.5 or 25 mg for adults, which may be adjusted by a healthcare provider based on response and tolerability.
- The medication works by increasing levels of neurotransmitters like dopamine and norepinephrine in the brain, helping improve attention, focus, and behavioral control in people with ADHD.
Important Considerations
- As a stimulant medication, Mydayis carries risks including potential for abuse, cardiovascular effects, and psychiatric side effects, and it may interact with certain medications 1.
- Common side effects include decreased appetite, insomnia, dry mouth, and increased heart rate.
- Patients should avoid taking Mydayis with MAO inhibitors and should disclose all medications they're taking to their healthcare provider.
Clinical Guidelines and Recommendations
- According to recent studies, stimulant medications like Mydayis are first-line treatments for ADHD due to their efficacy and safety profile 1.
- However, it's crucial to weigh the benefits against potential risks, especially in patients with preexisting conditions or those taking other medications.
- Regular monitoring of pulse, blood pressure, and potential side effects is recommended when prescribing Mydayis 1.
From the Research
Definition and Overview of Mydayis
- Mydayis is a medication used to treat Attention Deficit Hyperactivity Disorder (ADHD) 2.
- It is a psychostimulant, which works by increasing the levels of certain neurotransmitters in the brain, such as dopamine and norepinephrine 2.
- Mydayis is a combination of dextroamphetamine and amphetamine, which are both stimulants commonly used to treat ADHD 3, 2.
Mechanism of Action
- The primary pharmacologic effect of Mydayis is to increase central dopamine and norepinephrine activity, which impacts executive and attentional function 2.
- Mydayis actions include dopamine and norepinephrine transporter inhibition, vesicular monoamine transporter 2 (VMAT-2) inhibition, and monoamine oxidase activity inhibition 2.
Side Effects and Risks
- Common side effects of Mydayis include loss of appetite, sleep problems, and mood disturbances 4.
- Misuse of stimulants like Mydayis can be associated with dangers including psychosis, myocardial infarction, cardiomyopathy, and even sudden death 5.
- Long-term safety studies and education on the health risks associated with misuse of Mydayis are imperative 5.